No effect of B vitamins on ADMA levels in patients at increased cardiovascular risk

A M E Spoelstra-de Man, T Teerlink, C B Brouwer, J A Rauwerda, C D A Stehouwer, Y M Smulders

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

OBJECTIVE: Asymmetric dimethylarginine (ADMA) is a recently identified potent cardiovascular risk factor. ADMA levels are increased in hyperhomocysteinaemia and the metabolism of ADMA is linked with that of homocysteine in several ways. Treatment with B vitamins effectively reduces homocysteine levels, but studies investigating the effect on ADMA levels are scarce and show conflicting results. In this study we evaluated the effect of treatment with B vitamins on ADMA levels in two high cardiovascular risk populations.

METHODS: In study I, 110 siblings of patients with clinical atherosclerotic disease and postmethionine hyperhomocysteinaemia were treated with 5 mg of folic acid and 250 mg of pyridoxine or placebo, and were analysed after 1 year. In study II, 41 patients with type 2 diabetes and mild hyperhomocysteinaemia were analysed after 6 months treatment with 5 mg of folic acid or placebo.

RESULTS: A correlation between baseline homocysteine and ADMA levels was found, which was partly due to confounding by renal function. Homocysteine levels decreased by 43% in study I and by 28% in study II. In both studies, treatment with B vitamins had no effect at all on ADMA, arginine/ADMA ratio and SDMA levels. This result was confirmed in multiple linear regression analyses with adjustment for baseline values and gender.

CONCLUSIONS: Our studies indicate that B vitamins, despite causing a substantial reduction in plasma homocysteine levels, have no beneficial effect on ADMA levels.

Original languageEnglish
Pages (from-to)495-501
Number of pages7
JournalClinical Endocrinology
Volume64
Issue number5
DOIs
Publication statusPublished - May 2006

Cite this

@article{0ac5b3fcbf17467aacad75bf29574993,
title = "No effect of B vitamins on ADMA levels in patients at increased cardiovascular risk",
abstract = "OBJECTIVE: Asymmetric dimethylarginine (ADMA) is a recently identified potent cardiovascular risk factor. ADMA levels are increased in hyperhomocysteinaemia and the metabolism of ADMA is linked with that of homocysteine in several ways. Treatment with B vitamins effectively reduces homocysteine levels, but studies investigating the effect on ADMA levels are scarce and show conflicting results. In this study we evaluated the effect of treatment with B vitamins on ADMA levels in two high cardiovascular risk populations.METHODS: In study I, 110 siblings of patients with clinical atherosclerotic disease and postmethionine hyperhomocysteinaemia were treated with 5 mg of folic acid and 250 mg of pyridoxine or placebo, and were analysed after 1 year. In study II, 41 patients with type 2 diabetes and mild hyperhomocysteinaemia were analysed after 6 months treatment with 5 mg of folic acid or placebo.RESULTS: A correlation between baseline homocysteine and ADMA levels was found, which was partly due to confounding by renal function. Homocysteine levels decreased by 43{\%} in study I and by 28{\%} in study II. In both studies, treatment with B vitamins had no effect at all on ADMA, arginine/ADMA ratio and SDMA levels. This result was confirmed in multiple linear regression analyses with adjustment for baseline values and gender.CONCLUSIONS: Our studies indicate that B vitamins, despite causing a substantial reduction in plasma homocysteine levels, have no beneficial effect on ADMA levels.",
keywords = "Adolescent, Adult, Arginine/analogs & derivatives, Atherosclerosis/blood, Cardiovascular Diseases/blood, Diabetes Mellitus, Type 2/blood, Double-Blind Method, Drug Administration Schedule, Female, Folic Acid/therapeutic use, Humans, Hyperhomocysteinemia/blood, Linear Models, Male, Middle Aged, Pyridoxine/therapeutic use, Risk Factors, Time Factors, Treatment Failure, Vitamin B Complex/therapeutic use",
author = "{Spoelstra-de Man}, {A M E} and T Teerlink and Brouwer, {C B} and Rauwerda, {J A} and Stehouwer, {C D A} and Smulders, {Y M}",
year = "2006",
month = "5",
doi = "10.1111/j.1365-2265.2006.02497.x",
language = "English",
volume = "64",
pages = "495--501",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "5",

}

No effect of B vitamins on ADMA levels in patients at increased cardiovascular risk. / Spoelstra-de Man, A M E; Teerlink, T; Brouwer, C B; Rauwerda, J A; Stehouwer, C D A; Smulders, Y M.

In: Clinical Endocrinology, Vol. 64, No. 5, 05.2006, p. 495-501.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - No effect of B vitamins on ADMA levels in patients at increased cardiovascular risk

AU - Spoelstra-de Man, A M E

AU - Teerlink, T

AU - Brouwer, C B

AU - Rauwerda, J A

AU - Stehouwer, C D A

AU - Smulders, Y M

PY - 2006/5

Y1 - 2006/5

N2 - OBJECTIVE: Asymmetric dimethylarginine (ADMA) is a recently identified potent cardiovascular risk factor. ADMA levels are increased in hyperhomocysteinaemia and the metabolism of ADMA is linked with that of homocysteine in several ways. Treatment with B vitamins effectively reduces homocysteine levels, but studies investigating the effect on ADMA levels are scarce and show conflicting results. In this study we evaluated the effect of treatment with B vitamins on ADMA levels in two high cardiovascular risk populations.METHODS: In study I, 110 siblings of patients with clinical atherosclerotic disease and postmethionine hyperhomocysteinaemia were treated with 5 mg of folic acid and 250 mg of pyridoxine or placebo, and were analysed after 1 year. In study II, 41 patients with type 2 diabetes and mild hyperhomocysteinaemia were analysed after 6 months treatment with 5 mg of folic acid or placebo.RESULTS: A correlation between baseline homocysteine and ADMA levels was found, which was partly due to confounding by renal function. Homocysteine levels decreased by 43% in study I and by 28% in study II. In both studies, treatment with B vitamins had no effect at all on ADMA, arginine/ADMA ratio and SDMA levels. This result was confirmed in multiple linear regression analyses with adjustment for baseline values and gender.CONCLUSIONS: Our studies indicate that B vitamins, despite causing a substantial reduction in plasma homocysteine levels, have no beneficial effect on ADMA levels.

AB - OBJECTIVE: Asymmetric dimethylarginine (ADMA) is a recently identified potent cardiovascular risk factor. ADMA levels are increased in hyperhomocysteinaemia and the metabolism of ADMA is linked with that of homocysteine in several ways. Treatment with B vitamins effectively reduces homocysteine levels, but studies investigating the effect on ADMA levels are scarce and show conflicting results. In this study we evaluated the effect of treatment with B vitamins on ADMA levels in two high cardiovascular risk populations.METHODS: In study I, 110 siblings of patients with clinical atherosclerotic disease and postmethionine hyperhomocysteinaemia were treated with 5 mg of folic acid and 250 mg of pyridoxine or placebo, and were analysed after 1 year. In study II, 41 patients with type 2 diabetes and mild hyperhomocysteinaemia were analysed after 6 months treatment with 5 mg of folic acid or placebo.RESULTS: A correlation between baseline homocysteine and ADMA levels was found, which was partly due to confounding by renal function. Homocysteine levels decreased by 43% in study I and by 28% in study II. In both studies, treatment with B vitamins had no effect at all on ADMA, arginine/ADMA ratio and SDMA levels. This result was confirmed in multiple linear regression analyses with adjustment for baseline values and gender.CONCLUSIONS: Our studies indicate that B vitamins, despite causing a substantial reduction in plasma homocysteine levels, have no beneficial effect on ADMA levels.

KW - Adolescent

KW - Adult

KW - Arginine/analogs & derivatives

KW - Atherosclerosis/blood

KW - Cardiovascular Diseases/blood

KW - Diabetes Mellitus, Type 2/blood

KW - Double-Blind Method

KW - Drug Administration Schedule

KW - Female

KW - Folic Acid/therapeutic use

KW - Humans

KW - Hyperhomocysteinemia/blood

KW - Linear Models

KW - Male

KW - Middle Aged

KW - Pyridoxine/therapeutic use

KW - Risk Factors

KW - Time Factors

KW - Treatment Failure

KW - Vitamin B Complex/therapeutic use

U2 - 10.1111/j.1365-2265.2006.02497.x

DO - 10.1111/j.1365-2265.2006.02497.x

M3 - Article

VL - 64

SP - 495

EP - 501

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 5

ER -